Shaily Engineering Plastics reports strong growth, driven by healthcare

Shaily Engineering Plastics Limited recorded a substantial 22% increase in revenue from operations for fiscal year 2024-25, reaching H73,811.94 Cr, compared to H61,597.36 Cr in the previous fiscal year. This growth was primarily driven by a 53% surge in revenue from the healthcare segment. Profit before tax (PBT) also saw a significant jump of 71% to H9,465.81 Cr, up from H4,868.63 Cr in fiscal year 2023-24.

The company's EBITDA grew by 45% to H178.4 Cr, with EBITDA margins expanding to 22.7% in fiscal year 2024-25. Total capital expenditure for the year was H72.2 Cr, mainly directed towards a new pharma plant. The board of directors has recommended a final dividend of H2 per equity share for fiscal year 2024-25.

Shaily Engineering Plastics highlights its strategic investments in capabilities, infrastructure, and customer relationships, particularly in its healthcare vertical, as key drivers of this performance. The company's focus on high-precision component manufacturing and IP-led solutions in drug delivery systems positions it for continued growth.